Reach Us +1-217-403-9671
ROLE OF Lipid Based Drug Delivery Systems In Bioavailability Enhancement | 8355
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

ROLE OF Lipid based drug delivery systems in bioavailability enhancement

International Conference & Exhibition Bioequivalence and Bioavailability

Dr. Praveen S. Hiremath

ScientificTracks Abstracts: Bioavailability & Bioequivalence

DOI: 10.4172/0975-0851.1000001

T he focus of pharmaceutical research is being steadily shifted from the development of new chemical entities (NCEs) to the development of novel drug delivery systems of existing drug molecules to maximize their effectiveness in terms of therapeutic action and patent protection. This is due to decreasing number of NCEs approved by FDA, in 2008 only 21 new drugs were approved for marketing in the United States. To add to this issue, more than 50% of the NCEs are poorly soluble and poorly bioavailable. Lipid based drug delivery systems have been known to enhance the bioavailability of poorly soluble and/or poorly permeable drugs. Among the lipid based formulations, proliposomes are one of the very promising drug delivery systems in enhancing oral bioavailability of drugs. The oral delivery of liposomes could be improved by enhancing the ability of liposomes to retain their integrity at the site of absorption which could be achieved by formulating them into proliposomes. We have developed the proliposomal formulations of exemestane, a breast cancer drug, which suffers from poor solubility, first pass metabolism and bioavailability problems. These proliposomal formulations of exemestane might lead to improved oral bioavailability due to enhanced solubility, permeation and, thus absorption